Cargando…
In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy
BACKGROUND: In hypertrophic cardiomyopathy (HCM), autopsy studies revealed both increased focal and diffuse deposition of collagen fibers. Late gadolinium enhancement imaging (LGE) detects focal fibrosis, but is unable to depict interstitial fibrosis. We hypothesized that with T1 mapping, which is e...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026831/ https://www.ncbi.nlm.nih.gov/pubmed/24766828 http://dx.doi.org/10.1186/1532-429X-16-28 |
_version_ | 1782316906962747392 |
---|---|
author | Brouwer, Wessel P Baars, Emma N Germans, Tjeerd de Boer, Karin Beek, Aernout M van der Velden, Jolanda van Rossum, Albert C Hofman, Mark BM |
author_facet | Brouwer, Wessel P Baars, Emma N Germans, Tjeerd de Boer, Karin Beek, Aernout M van der Velden, Jolanda van Rossum, Albert C Hofman, Mark BM |
author_sort | Brouwer, Wessel P |
collection | PubMed |
description | BACKGROUND: In hypertrophic cardiomyopathy (HCM), autopsy studies revealed both increased focal and diffuse deposition of collagen fibers. Late gadolinium enhancement imaging (LGE) detects focal fibrosis, but is unable to depict interstitial fibrosis. We hypothesized that with T1 mapping, which is employed to determine the myocardial extracellular volume fraction (ECV), can detect diffuse interstitial fibrosis in HCM patients. METHODS: T1 mapping with a modified Look-Locker Inversion Recovery (MOLLI) pulse sequence was used to calculate ECV in manifest HCM (n = 16) patients and in healthy controls (n = 14). ECV was determined in areas where focal fibrosis was excluded with LGE. RESULTS: The total group of HCM patients showed no significant changes in mean ECV values with respect to controls (0.26 ± 0.03 vs 0.26 ± 0.02, p = 0.83). Besides, ECV in LGE positive HCM patients was comparable with LGE negative HCM patients (0.27 ± 0.03 vs 0.25 ± 0.03, p = 0.12). CONCLUSIONS: This study showed that HCM patients have a similar ECV (e.g. interstitial fibrosis) in myocardium without LGE as healthy controls. Therefore, the additional clinical value of T1 mapping in HCM seems limited, but future larger studies are needed to establish the clinical and prognostic potential of this new technique within HCM. |
format | Online Article Text |
id | pubmed-4026831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40268312014-05-21 In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy Brouwer, Wessel P Baars, Emma N Germans, Tjeerd de Boer, Karin Beek, Aernout M van der Velden, Jolanda van Rossum, Albert C Hofman, Mark BM J Cardiovasc Magn Reson Research BACKGROUND: In hypertrophic cardiomyopathy (HCM), autopsy studies revealed both increased focal and diffuse deposition of collagen fibers. Late gadolinium enhancement imaging (LGE) detects focal fibrosis, but is unable to depict interstitial fibrosis. We hypothesized that with T1 mapping, which is employed to determine the myocardial extracellular volume fraction (ECV), can detect diffuse interstitial fibrosis in HCM patients. METHODS: T1 mapping with a modified Look-Locker Inversion Recovery (MOLLI) pulse sequence was used to calculate ECV in manifest HCM (n = 16) patients and in healthy controls (n = 14). ECV was determined in areas where focal fibrosis was excluded with LGE. RESULTS: The total group of HCM patients showed no significant changes in mean ECV values with respect to controls (0.26 ± 0.03 vs 0.26 ± 0.02, p = 0.83). Besides, ECV in LGE positive HCM patients was comparable with LGE negative HCM patients (0.27 ± 0.03 vs 0.25 ± 0.03, p = 0.12). CONCLUSIONS: This study showed that HCM patients have a similar ECV (e.g. interstitial fibrosis) in myocardium without LGE as healthy controls. Therefore, the additional clinical value of T1 mapping in HCM seems limited, but future larger studies are needed to establish the clinical and prognostic potential of this new technique within HCM. BioMed Central 2014-04-25 /pmc/articles/PMC4026831/ /pubmed/24766828 http://dx.doi.org/10.1186/1532-429X-16-28 Text en Copyright © 2014 Brouwer et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
spellingShingle | Research Brouwer, Wessel P Baars, Emma N Germans, Tjeerd de Boer, Karin Beek, Aernout M van der Velden, Jolanda van Rossum, Albert C Hofman, Mark BM In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy |
title | In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy |
title_full | In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy |
title_fullStr | In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy |
title_full_unstemmed | In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy |
title_short | In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy |
title_sort | in-vivo t1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026831/ https://www.ncbi.nlm.nih.gov/pubmed/24766828 http://dx.doi.org/10.1186/1532-429X-16-28 |
work_keys_str_mv | AT brouwerwesselp invivot1cardiovascularmagneticresonancestudyofdiffusemyocardialfibrosisinhypertrophiccardiomyopathy AT baarsemman invivot1cardiovascularmagneticresonancestudyofdiffusemyocardialfibrosisinhypertrophiccardiomyopathy AT germanstjeerd invivot1cardiovascularmagneticresonancestudyofdiffusemyocardialfibrosisinhypertrophiccardiomyopathy AT deboerkarin invivot1cardiovascularmagneticresonancestudyofdiffusemyocardialfibrosisinhypertrophiccardiomyopathy AT beekaernoutm invivot1cardiovascularmagneticresonancestudyofdiffusemyocardialfibrosisinhypertrophiccardiomyopathy AT vanderveldenjolanda invivot1cardiovascularmagneticresonancestudyofdiffusemyocardialfibrosisinhypertrophiccardiomyopathy AT vanrossumalbertc invivot1cardiovascularmagneticresonancestudyofdiffusemyocardialfibrosisinhypertrophiccardiomyopathy AT hofmanmarkbm invivot1cardiovascularmagneticresonancestudyofdiffusemyocardialfibrosisinhypertrophiccardiomyopathy |